Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epertinib - Shionogi

Next Previous
X
Search
Drug Profile

Epertinib - Shionogi

Alternative Names: EOC 611; S 222611

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Class Antineoplastics; Morpholines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 26 Sep 2022 No development reported - Phase-II for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)
  • 15 Jan 2021 EOC Pharma submits a Clinical Trial Application to the National Medical Products Administration for Brain metastasis (in patients with Breast cancer) before January 2021 (EOC Pharma's pipeline, January 2021)
  • 15 Jan 2021 EOC Pharma plans a clinical trial for Brain metastasis (In breast cancer patients) in China (PO) (EOC Pharma's pipeline, January 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top